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ABSTRACT 
Insulin resistance is closely related to intramyocellular lipid (IMCL) accumulation, and both 
are associated with increasing age. It remains to be determined to what extent perturbations in 
IMCL metabolism are related to the ageing process per se. On two separate occasions whole-
body and muscle insulin sensitivity (euglycaemic hyperinsulinaemic clamp with 2-
deoxyglucose) and fat utilisation during 1 h of exercise at 50% VO2max ([U-
13
C]palmitate 
infusion combined with electron microscopy of IMCL) were determined in young lean (YL), 
old lean (OL), and old overweight (OO) males. OL displayed comparable IMCL content and 
insulin sensitivity to YL, whereas OO were markedly insulin resistant and had over 2-fold 
greater IMCL in the subsarcolemmal (SSL) region. Indeed, whereas the plasma free fatty acid 
rate of appearance and disappearance was twice that of YL in both OL and OO, SSL only 
increased during exercise in OO. Thus, skeletal muscle insulin resistance and lipid 
accumulation often observed in older individuals are likely due to lifestyle factors, rather than 
inherent ageing of skeletal muscle as usually reported. However, age per se appears to cause 
exacerbated adipose tissue lipolysis, suggesting that strategies to reduce muscle lipid delivery 
and improve adipose tissue function may be warranted in older overweight individuals.    
Page 2 of 31Diabetes
 3
The global prevalence of type 2 diabetes is most apparent in older people (1), and it is 
estimated that the number of people over 65 years of age with diabetes will have increased 
4.5 fold by 2050 (2). Gaining mechanistic insight of age related insulin resistance and 
strategies to improve insulin sensitivity with age are clearly warranted. Although ageing is 
associated with insulin resistance, age per se does not appear to cause insulin resistance (3, 4, 
5). Several factors that likely contribute to age related insulin resistance include increased 
abdominal adiposity and reduced physical activity (3, 4), along with declines in muscle mass 
(6, 7). Of note, intramyocellular lipid (IMCL) accumulates with age, particularly in 
subsarcolemmal (SSL) regions (8), and has been strongly associated with insulin resistance 
(9, 10, 11, 12). Indeed, SSL lipid accumulation has been linked to the accumulation of 
metabolites, such as diacylglycerol (DAG) and ceramide, thought by some (13, 14, 15), but 
not others (16), to contribute to impaired insulin-stimulated muscle glucose uptake. 
Nevertheless, it remains contentious as to which factors associated with age influence IMCL 
accumulation. 
 
The accumulation of IMCL and associated metabolites likely result from an imbalance 
between muscle lipid delivery and oxidation. Indeed, studies have demonstrated reduced free 
fatty acid (FFA) oxidation in older people compared to young, despite whole-body lipolysis 
and plasma FFA availability being greater at rest and during exercise at the same absolute 
and relative intensities (17, 18). Linked to this, several studies have suggested age related 
blunting of FFA oxidation and increased IMCL accumulation are a result of reduced muscle 
mitochondrial content (8) and function (3, 19, 20) with age. However, increased adiposity 
and reduced habitual levels of physical activity also affect FFA flux and oxidation in older 
individuals (21), and studies to date have not controlled for these factors when investigating 
changes in muscle IMCL metabolism with age. Therefore, we investigated the effect of 
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ageing on whole-body and skeletal muscle lipid metabolism, with parallel characterization of 
muscle insulin sensitivity, in lean young and older individuals matched for estimated habitual 
physical activity levels and body composition. To determine the effect of adiposity and 
reduced physical activity on the ageing process, the older lean individuals were also 
compared to a group of older overweight individuals matched for lean mass. We 
hypothesized that an age-associated imbalance between FFA delivery and oxidation in 
skeletal muscle during exercise would only be observed in older overweight individuals, 
which would manifest as reduced IMCL oxidation and increased IMCL storage, particularly 
in the SSL region, and be associated with skeletal muscle insulin resistance.  
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RESEARCH DESIGN AND METHODS 
 
Subjects 
Seven young lean, (YL; BMI <25 kg/m
-2
), old lean (OL; body mass index (BMI) <25 kg/m
-
2
), and old overweight (OO; BMI >27 kg/m
-2
) healthy, recreationally active male volunteers 
participated in the present study, which was approved by the University of Nottingham’s 
Medical School Ethics Committee in accordance with the Declaration of Helsinki. Before 
taking part, all subjects underwent routine medical screening and completed a quality of life 
(SF-36) questionnaire indicating their ability to perform physical activity. They also 
completed a general health questionnaire indicating their habitual frequency of performing 
moderate to high intensity physical activities including team sports, resistance exercise, 
running, cycling, and swimming (Table 1). Informed consent was obtained from all 
volunteers before participating in the study and they were made aware that they were free to 
withdraw at any point. On a separate visit all subjects performed an incremental exhaustive 
exercise test on an electronic-braked cycle ergometer (Excalibur, Lode, The Netherlands) to 
determine their maximal rate of oxygen consumption (VO2max; Quark CPET, Cosmed, Italy) 
and the workload that would elicit 50% VO2max, which was confirmed in a familiarization 
visit at least 3 days later.   
 
Experimental Protocol 
Subjects attended the laboratory on two occasions separated by at least 1 week. On the first 
occasion they arrived at 0800 after an overnight fast, having abstained from exercise and 
alcohol for the previous 48 hours, in order to determine their body composition and insulin 
sensitivity. Trunk, leg and arm composition using standardized regions were analyzed by a 
single operator using dual energy x-ray absorptiometry (DEXA; Lunar Prodigy, GE 
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Healthcare, US). Subjects then rested semi-supine on a bed and underwent a 3 h euglycaemic 
(4.5 mmol/L) hyperinsulinaemic (60 mU·m
-2
·min
-1
) clamp (22) in combination with the 
intravenous infusion of 2-deoxy-D-glucose (2DG; 6 mg·kg
-1
·h
-1
) to assess whole body and 
skeletal muscle insulin sensitivity, respectively. 2DG is a glucose analogue that closely 
resembles glucose in the characteristics of its transport but is metabolized by muscle to the 6-
phosphate derivative (2DG6P). Thus, muscle 2DG6P is effectively trapped and its content 
can be determined as a direct measure of muscle glucose uptake (23). Indirect calorimetry 
(GEMNutrition Ltd, UK) was performed prior to and after 2 h of the clamp. 
 
On the second visit, volunteers again reported to the laboratory following an overnight fast 
and rested semi-supine on a bed for infusion of NaH
13
CO3 (Cambridge Isotope Laboratories, 
USA) and [U-
13
C]palmitate (99% enriched; Cambridge Isotope Laboratories, USA) bound to 
4.5% human serum albumin (Zenalb 4.5, Bio Products Laboratory Limited, UK) at a ratio of 
approximately 3:1 (1.94:0.64 µmol/L). Following a 63.75 µg/kg bolus of NaH
13
CO3 to prime 
the bicarbonate pool (24), [U-
13
C]palmitate was infused at a rate of 0.19 mg·kg
-1
·h
-1
for 2 h, 
which then increased to 0.28 mg·kg
-1
·h
-1
 at the onset of 1 h cycling exercise at 50% VO2max.  
 
Sample collection and analysis 
During the first visit arterialized-venous blood (25) was obtained before and every 5 min 
throughout the clamp for measurement of blood glucose concentration (Stat Analyzer, YSI 
Inc, USA) and every 30 min throughout the clamp for subsequent analysis of serum insulin 
using a solid-phase 
125
I radioimmunoassay kit (Human Insulin Assay, Merck Millipore, 
USA), and plasma 2DG via gas-chromatography mass-spectrometry (GC-MS; MD800, 
Fisons, UK; 23). Needle biopsy samples were obtained from the vastus lateralis (26) before 
and immediately after the clamp and snap frozen in liquid nitrogen. At a later date, 30 mg of 
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wet muscle was pulverized for analysis of 2DG6P content using a commercial 
spectrophotometric kit method (Cosmo Bio Ltd, Japan; 27). In addition, approximately 20 mg 
of wet muscle from the baseline biopsy was used to determine muscle citrate synthase (CS) 
maximal activity spectrophotometrically (28) and carnitine palmitoyltransferase 1 (CPT1) 
maximal activity using a radioisotope assay (29). Total RNA was also extracted from 
approximately 20 mg of wet muscle tissue (Trizol reagent; Invitrogen Ltd, UK) and following 
generation of first-strand cDNA (SuperScript III kit; Invitrogen Ltd, UK), the relative 
abundance of mRNA of 12 genes from pathways involved in FFA oxidation and IMCL 
metabolism was determined using RT-PCR microfluidic cards (Applied Biosystems, USA, 
29).  
 
On the second experimental visit, blood samples were obtained before and every 10 min 
during exercise, analyzed immediately for blood lactate concentration (2300 Stat Analyzer; 
YSI Inc, USA) and, following centrifugation, plasma was stored at -80
◦
C. Plasma treated with 
tetrahydrolipostatin (30 µg/mL plasma) was analyzed for total FFA (NEFA C kit, WAKO 
Chemicals, Germany) on an automated analyzer (ABX Pentra 400, Horiba Medical Ltd., 
France). Plasma separated from EGTA treated blood was analyzed for [U-
13
C]palmitate and 
palmitate by TSQ triple quadrupole gas-chromatography-mass-spectrometry/mass 
spectrometry (GC-MS/MS, Thermo, UK) and GC-MS (MD800, Fisons, UK ) respectively, 
after addition of a heptadecanoic internal standard and derivatization to their methyl esters 
(30). High-performance liquid-chromatography (HPLC) with electrochemical detection was 
used to measure plasma epinephrine and norepinephrine concentrations (31). Breath samples 
were also collected every 10 min during exercise via one-way valve bags and introduced into 
vacuumed glass tubes (Exetainer, Labco Ltd, UK) for subsequent 
13
CO2 enrichment analysis 
by continuous-flow isotope-ratio MS (CF-IRMS; AP2003 Breath Gas System, Analytical 
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Precision, UK; 32). During the last 10 min of exercise when the 
13
CO2 production was at a 
steady-state and therefore no longer being retained by the muscle (negating the requirement 
for an acetate recovery factor), indirect calorimetry was performed (Quark CPET system, 
Cosmed, Italy). In addition, a vastus lateralis needle biopsy (26) was obtained immediately 
before and after the exercise bout and processed within 10 seconds to minimise ex vivo 
changes in intracellular metabolism and contamination of the IMCL pool by extracellular 
adipocytes. A 5 mg portion buffered in ice-cold 3% gluteraldehyde/0.1 M sodium cacodylate 
(pH 7.4) and stored at 4
◦
C for subsequent electron microscopy processing, and the remainder 
immediately frozen in lipid nitrogen. Samples for transmission electron microscopy were 
fixed in 1% osmium tetroxide, dehydrated in graded ethanol series and embedded in two 
resin blocks. Three ultrathin 70-90 nanometer sections were cut from each block, mounted on 
copper grids, and stained in uranyl acetate and lead acetate, with one section randomly 
selected to be visualized at x4200 magnification. Approximately 40 fields of view from up to 
40 longitudinal fibres were systematically randomly selected by a blinded operator using the 
corners of copper grid squares as a guide. This method obtained at least 6 images per sample 
containing a SSL region, which was required for reproducible estimation of IMCL droplet 
(LD) characteristics. Images were analyzed using Image J to determine percentage of 
intermyofibrillar (IMF) and SSL area covered by LD, LD size, and total number of LD per 
square micrometer of local tissue area, which have been previously shown (8) to produce 
values similar to 3D stereology volume estimates (33). In addition, a portion of the pre-
exercise biopsy was freeze-dried, dissected free of visible blood and connective tissue, 
pulverized and used for the quantification of DAG and ceramide. Briefly, 50 ng internal 
standard (1,3[d5]-15:0 DAG) was added to 5 mg muscle, from which total muscle lipids were 
extracted in CHCl3:MeOH:H2O and the most abundant DAG (diC16:0, C16:0/C18:1, 
diC18:1) and ceramide (C16:0, C18:0, C18:1, C20:0, C24:1, C24:0) species were quantified 
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by LC-MS-MS (Quattro Ultima, Micromass Ltd, UK; 34, 35). Peak areas were normalised to 
the internal standard and converted to absolute concentrations using a standard curve specific 
for each species. A further portion of muscle powder was also used for the determination of 
muscle creatine, phosphocreatine, glycogen, lactate, and acetylcarnitine as previously 
described (36).  
 
Calculations 
Insulin sensitivity index (SIClamp) was calculated using the equation of Matsuda and DeFronzo 
(SIClamp = M/(G × ∆I); 22) where steady-state (120-180 min) glucose disposal (M) is 
normalized for steady-state blood glucose concentration (G; mmol/L) and the difference 
between fasting and steady-state plasma insulin concentrations (∆I; mU/L). Indirect 
calorimetry calculations both at rest and during exercise were performed according to non-
protein stoichiometric equations (37) and normalised to lean body mass (DEXA). The rate of 
appearance (Ra), disappearance (Rd), and oxidation of palmitate during the final 10 min of 
exercise were used to calculate total plasma FFA kinetics by dividing the fractional 
contribution of plasma palmitate to total plasma FFA concentration as previously described 
(38). The contribution of other fat sources was calculated by subtracting plasma FFA 
oxidation from total fat oxidation calculated via indirect calorimetry.  
 
Statistical Analysis 
Differences between groups at baseline, and within and between groups during exercise, were 
analyzed using a one- and two-way ANOVA, respectively (GraphPad Prism 6.0, GraphPad 
Software Inc, USA). When a significant main effect was observed, Tukey’s and Sidak’s post-
hoc test was performed, respectively, to identify individual differences. Statistical 
significance was set at P<0.05, and all values are presented as means ± SEM.  
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RESULTS 
 
Subject characteristics 
In line with the inclusion criteria OL and YL had a similar body composition. However, OO 
had greater trunk, arm and leg fat masses compared with OL and YL subjects, but similar 
whole-body, arm and leg fat free mass (Table 1). Furthermore, self-reported levels of habitual 
physical activity were similar between OL and YL, but less in OO compared to OL. Both OL 
and OO had similar absolute (mL/min) and relative (mL·kg lbm
-1
·min
-1
) VO2max but these 
were less than in YL, as were the corresponding absolute workload and heart rate at 50% 
VO2max.  
 
Skeletal muscle insulin sensitivity and lipid metabolite content 
Steady-state serum insulin and glucose disposal during the euglycaemic hyperinsulinaemic 
clamp for OL, YL, and OO were (119.6 ± 7.0, 117.7 ± 7.8, and 137.5 ± 4.3 mU/L) and (57.8 
± 5.6, 65.1 ± 5.6, and 41.6 ± 5.2 µmol·kg lbm
-1
·min
-1
; P<0.01 OL and YL vs. OO), 
respectively. As such, OL and YL had similar SIClamp that were 57% (P<0.05) and 86% 
(P<0.01) greater than OO, respectively (Figure 1A). Furthermore, muscle 2DG6P 
accumulation during the clamp was not different between OL and YL, but was less than half 
that of YL in OO (P<0.01; Figure 1B), and OL and YL had similar steady-state plasma 2DG 
concentrations during the clamp, which were less than OO (50.0 ± 1.9 and 48.8 ± 2.2 vs. 72.6 
± 2.2 µmol/L, respectively; P<0.05; Figure 1C). Insulin-stimulated resting energy 
expenditure increased by more than 10% in both OL (P<0.01) and YL (P<0.05), but did not 
change in OO (P=1.0; Figure 1D). There were no differences in muscle DAG species 
between groups with the exception of diC18:1, which was lower in OL and YL compared to 
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OO (both P<0.05; Figure 2A). Similarly most muscle ceramide species did not differ except 
C20:0, which was lower in YL compared to OO (P<0.01; Figure 2B).  
 
Whole body substrate metabolism during exercise 
Whole body energy expenditure during the last 10 min of 1 h of exercise at 50% VO2max 
was lower in OL and OO compared to YL (both P<0.05; Figure 3A), but the relative 
contribution from total fat oxidation to energy expenditure was similar (42.4 ± 3.1, 40.1 ± 4.6 
and 43.9 ± 6.5%, respectively). Nevertheless, the oxidation of fat from sources other than 
plasma FFA (i.e. predominantly from IMCL) was almost 3-fold lower in OL and OO 
compared to YL (both P<0.05; Figure 3A), such that the relative contribution of these sources 
to total fat oxidation was around half that of YL (38.7 ± 7.7 and 45.0 ± 7.9 vs. 71.9 ± 3.1 %, 
respectively; P<0.01; Figure 3A). Plasma FFA Ra was similar between OL and OO (24.2 ± 
2.9 vs. 24.3 ± 5.3 µmol·kg lbm
-1
·min
-1
), and greater compared to YL (13.8 ± 2.3 µmol·kg 
lbm
-1
·min
-1
; P<0.05), but there were no differences in plasma FFA concentration (0.62 ± 
0.06, 0.58 ± 0.09, and 0.45 ± 0.08 for OL, OO and YL, respectively). Plasma FFA Rd was 
also similar between OL and OO, but greater in OL compared to YL (P<0.05; Figure 3B). In 
contrast, whereas the percentage of plasma FFA Rd oxidized was similar between OL and 
YL (54.4 ± 5.9 and 52.7 ± 3.4%, respectively; Figure 3C), it was lower in OO (42.2 ± 1.2%) 
compared to OL (P<0.05) and YL (P=0.07; Figure 3C).  
 
From similar baseline concentrations, plasma norepinephrine increased to a similar steady-
state in OL and OO throughout 1 h of exercise, and was around 1.5-fold greater than the 
steady-state concentration achieved in YL (both P<0.05 respectively; Figure 3D). However, 
there were no differences between groups in baseline or steady-state plasma epinephrine 
(0.25 ± 0.02 to. 0.53 ± 0.11, 0.25 ± 0.06 to 0.34 ± 0.06, and 0.24 ± 0.04 to 0.43 ± 0.06 
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nmol/L) or blood lactate (0.71 ± 0.06 to 1.50 ± 0.29, 0.97 ± 0.13 to 2.05 ± 0.31, and 0.87 ± 
0.09 to 1.73 ± 0.28 mmol/L) concentrations in OL, OO and YL, respectively. 
 
IMCL and skeletal muscle oxidative metabolism during exercise 
The area of SSL region covered by LD was similar between OL and YL at rest and did not 
change during exercise (Figure 4A). However, SSL area covered by LD in OO was almost 3-
fold greater at rest compared with YL (P<0.05) and increased during exercise (P<0.05), such 
that post-exercise it was greater than both OL (P<0.05) and YL (P<0.01; Figure 4A). This 
was predominantly due to a 25% increase in average SSL LD size in OO (P=0.05; Figure 
4B). In contrast, exercise caused a decrease (P<0.01) in both the number of IMF LD (0.024 ± 
0.001 to 0.017 ± 0.003, 0.022 ± 0.003 to 0.015 ± 0.002, and 0.023 ± 0.03 to 0.018 ± 
0.003LD/µm
2
 for OL, YL and OO, respectively) and area covered by LD (Figure 4C). The 
latter was isolated to a 40% reduction in IMF area covered by LD in YL (0.05; Figure 4C). 
Average IMF LD size was 45% greater in OO compared to OL and YL post-exercise (both 
P<0.01; Figure 4D).  
 
Resting skeletal muscle glycogen (Figure 5A), phosphocreatine (Figure 5B), and lactate 
(Figure 5C) content was similar between OL and YL and did not change measurably during 
exercise, whereas acetylcarnitine content increased during exercise by around 7 (P<0.001) 
and 3 fold (P<0.05), respectively. However, resting muscle glycogen and phosphocreatine 
content were lower (P<0.05) and muscle lactate content more than doubled during exercise 
(P<0.05) in OO. Nevertheless, there were no significant differences in maximal CS (116.8 ± 
12.6, 94.7 ± 8.8, and 84.1 ± 8.3 nmol·mg protein·
-1
min
-1
, respectively) or CPT1 (2.3 ± 0.3, 
1.8 ± 0.3, and 2.0 ± 0.1 nmol·mg protein·
-1
min
-1
, respectively) activities between OL, YL and 
OO, respectively, although the former tended to be greater in OL vs. OO (P=0.08). 
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Skeletal muscle gene expression 
The relative expression of 12 skeletal muscle transcripts involved in fatty oxidation and 
IMCL turnover are presented in Table 2. HADHB and PLIN2 expression were greater in OL 
compared to YL (P<0.05), whereas ACACB, SPTLC1, and DGKD expression were lower in 
YL compared to OO (all P<0.05). Furthermore, PLIN2 gene expression was greater in OL vs. 
OO (P<0.05) respectively. 
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DISCUSSION 
 
Insulin resistance is closely related to IMCL accumulation, and both are associated with 
increasing age. However, it remains to be determined to what extent perturbations in IMCL 
metabolism are related to the ageing process per se or secondary to age-related changes in 
lifestyle. Thus, by matching young and older volunteers for body composition and self-
reported habitual physical activity levels the present study demonstrated that lean older 
individuals display comparable IMCL content and insulin sensitivity to their younger 
counterparts. On the other hand, ageing per se appeared to cause an exacerbated lipolytic 
response to exercise due, at least in part, to an increased sympathetic response. Coupled with 
increased adiposity and reduced habitual physical activity levels in an age-matched group this 
resulted in SSL IMCL accumulation, and may mechanistically help explain the association 
between increased IMCL and skeletal muscle insulin resistance in older individuals.  
 
In line with several studies that suggest ageing per se does not cause insulin resistance (3, 4, 
5), there was no difference in whole-body glucose disposal, skeletal muscle 2DG6P 
accumulation, or the energy expenditure response during a euglycaemic hyperinsulinaemic 
clamp between old and young individuals matched for body composition and self-reported 
physical activity in the present study. Furthermore, the finding that whole-body and skeletal 
muscle insulin action was reduced in old overweight individuals with a similar lean body 
mass but lower self-reported physical activity supports the notion that lifestyle factors are 
more influential in the development of age-related insulin resistance (3, 4, 5, 39, 40, 41). A 
possible link between these factors and reduced skeletal muscle insulin sensitivity is the 
accumulation of SSL IMCL (9, 10) and associated lipid metabolites such as DAG and 
ceramide (13, 14, 15). Indeed, whereas there was no difference in SSL IMCL between lean 
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old and young, SSL IMCL was more than 2-fold higher in the older overweight individuals, 
which is in agreement with a 2 and 3-fold greater content observed in lean sedentary older 
individuals (8) and type 2 diabetes (9), respectively. However, although the skeletal muscle 
content of the predominant DAG and ceramide species were not different between lean old 
and young they were also not greater in old overweight, with the exception of diC18:1 DAG 
and C20:0 ceramide. Indeed, total muscle DAG and ceramide do not correlate well with 
insulin sensitivity but specific lipid species, particularly sarcolemmal saturated DAG, may 
influence insulin action (42). 
 
Why IMCL accumulates, particularly in the SSL region, is not clear, but several studies have 
demonstrated reduced FFA oxidation in older individuals despite increased whole body 
lipolysis and FFA availability compared to young at rest and during exercise (17, 18). Indeed, 
although the relative contribution of fat oxidation to total energy expenditure during exercise 
was not different between the young and old groups of the present study, there was an 
elevated plasma norepinephrine, FFA Ra, and FFA Rd response to exercise at the same 
relative intensity observed in both the lean and overweight older individuals, suggesting an 
effect of age per se on whole body responses. This would fit with previous reports that age 
associated increments in norepinephrine are independent of habitual physical activity and 
likely due increased sympathetic activity rather than reduced norepinephrine clearance (43). 
As a consequence, the relative contribution of IMCL to fat oxidation was reduced in both old 
lean and overweight compared to young individuals. This is remarkable given there was 
presumably a greater lipolytic stimulus to IMCL by norepinephrine in the older individuals 
(44, 45), and would suggest a potent inhibitory effect of plasma derived FFA or a blunted 
contraction induced IMCL hydrolysis. Furthermore, a novel finding of the present study was 
that, assuming similar rates of adipose tissue FFA re-esterification (where FFA released from 
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adipose tissue is reincorporated in a futile cycle), lean older individuals were able to oxidise a 
larger proportion of the excess FFA delivered during exercise compared to the older 
overweight individuals, where it deposited in SSL lipid droplets. This not only suggests that a 
more general, chronic imbalance between skeletal muscle FFA delivery and oxidation may 
contribute to IMCL accumulation, but also provides evidence for distinct roles of the 
localised IMCL pools. For example, the reduction in the number of IMF lipid droplets during 
exercise in the younger individuals suggests that this pool is used for muscle contraction, 
possibly in an ‘all or nothing’ fashion, whereas the deposition in the SSL pool suggests a role 
in buffering/trafficking of FFA influx (46), and perhaps insulin resistance. Interestingly, an 
improvement in insulin sensitivity has been previously observed with reduced SSL but not 
IMF IMCL following 10 to 12 weeks of exercise training where the capacity to oxidise FFA 
was increased (9, 10).  
 
In addition to reduced energy expenditure, such as observed during insulin-stimulated 
conditions of the present study, several mechanisms may explain the apparent inability of 
skeletal muscle of older overweight men to oxidize excess FFA delivery. For example, it has 
been suggested that aging is associated with impaired in vivo (19) and in vitro (3, 20) skeletal 
muscle mitochondrial ATP production, as well as a reduction in mitochondrial content (8), 
independently of adiposity. However, there was no difference in skeletal muscle maximal CS 
activity, maximal and relative CPT1 activity, or phosphocreatine, glycogen, lactate, and 
acetylcarnitine metabolism during exercise between the lean old and young participants in the 
present study, all of which are markers of in vivo muscle oxidative capacity. On the other 
hand, the disparity between old lean and old overweight participants in the ability to oxidize 
excess fatty acids may be due to differences in partitioning of skeletal muscle lipid and a 
diversion of fatty acids from oxidation towards synthesis of IMCL and other lipid species. 
Page 16 of 31Diabetes
 17 
For example, older lean individuals had a greater mRNA expression of perilipin 2 (PLIN2), a 
lipid droplet bound protein involved IMCL hydrolysis, and β-hydroxyacyl-CoA 
dehydrogenase (HADHB), an intramitochondrial enzyme that catalyses a rate-limiting step in 
β-oxidation, whereas old overweight had greater mRNA expression of acetyl-CoA 
carboxylase 2 (ACACB), which produces malonyl-CoA and inhibits CPT1, the rate limiting 
step for fatty acid entry into mitochondria. The PLIN2 expression in particular would fit 
previous reports in overweight individuals of impaired IMCL turnover and FFA release 
toward mitochondrial oxidation (44, 47). Furthermore, old overweight had a greater 
expression of diacylglycerol kinase delta (DGKD), which phosphorylates diacylglycerol to 
produce phosphatidic acid, and serine palmitoyltransferase (SPTLC1), a rate-limiting step in 
ceramide synthesis, compared to young lean individuals. Both of these observations fit with 
the greater muscle content of some of the DAG and ceramide species in the present study. A 
similar gene expression pattern has also been previously observed in insulin resistant 
individuals (48), but how this translates into protein content/activity and whether it is cause 
or effect requires further investigation.  
 
In conclusion, it is our assertion that increased IMCL (4, 8, 19) and reduced insulin 
sensitivity, mitochondrial capacity, and fat oxidation (3, 17, 18, 19, 20, 21, 49) often 
observed in older individuals are likely due to lifestyle factors rather than aging per se as 
commonly reported. However, age per se appears to increase the systemic sympathetic 
response to exercise and cause exacerbated adipose tissue lipolysis. Compounded by greater 
adiposity, the increased FA delivery appears to cause SSL IMCL accumulation in physically 
inactive older individuals. Thus, targeted strategies to reduce muscle lipid delivery and 
improve adipose tissue function may be warranted, particularly as physical inactivity appears 
to worsen the inability to suppress adipose tissue lipolysis in older individuals (50).    
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TABLES 
Table 1. Characteristics of young lean (YL), old lean (OL), and old overweight (OO) male 
participants. 
 YL OL OO 
n 7 7 7 
Age (y) 21.5 ± 1.0 69.7 ± 0.9
+++
 68.6 ± 0.8
***
 
Statin use (n) 0 3 4 
Body mass (kg) 71.8 ± 3.6 70.3 ± 2.4 86.3 ± 1.8
***,†††
 
BMI (kg/m
2
) 22.4 ± 0.7 24.0 ± 0.6 29.0 ± 0.7
***,†††
 
Lean mass (lbm; kg) 55.9 ± 3.2 51.3 ± 1.5 55.6 ± 1.9 
Arm lean mass (kg) 7.6 ± 0.4 6.7 ± 0.3 7.4 ± 0.3 
Leg lean mass (kg) 21.8 ± 0.4 18.3 ± 0.6 19.6 ± 0.7 
Trunk fat mass (kg) 4.6 ± 0.8 7.2 ± 1.1 16.0 ± 0.8
***,†††
 
Arm fat (kg) 0.9 ± 0.1 1.5 ± 0.2 2.6 ± 0.3
***,†††
 
Leg fat (kg) 4.7 ± 0.4 4.9 ± 0.4 7.4 ± 0.6
†
 
Fasting blood glucose 
(mmol/L) 
4.5 ± 0.1 4.7 ± 0.1 5.0 ± 0.1
*
 
Fasting serum insulin 
(mU/L) 
10.6 ± 1.4 7.4 ± 1.6 12.6 ± 1.2
†
 
HOMA IR 2.14 ± 0.32 1.60 ± 0.36 2.81 ± 0.25
†††
 
Physical activity 
frequency 
(occasions/week)  
3.5 ± 0.5  5.1 ± 1.2 1.8 ± 0.7
†
 
VO2max (L/min) 3.19 ± 0.19 2.26 ± 0.15
+++
 2.19 ± 0.13
***
 
VO2max (mL·kg lbm
-
1
·min
-1
) 
57.4 ± 2.4 44.6 ± 1.9
+++
 39.9 ± 1.5
***
 
Workload at 50% 
VO2max (W) 
93.0 ± 5.9 55.9 ± 5.8
+++
 46.3 ± 6.7
***
 
Heart rate at 50% 
VO2max (beats/min) 
137 ± 2 102 ± 7
+++
 102 ± 6
***
 
All values (n=7) are means ± standard error of the mean (SEM). ***P<0.001, OO different to 
corresponding YL value.
 †
P<0.05, 
†††
P<0.001, OO different to corresponding OL value. 
+++
P<0.001, OL different to corresponding YL value. 
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Table 2. Expression of skeletal muscle transcripts encoding proteins involved in fatty acid 
oxidation and IMCL in young lean (OO), old lean (OL), and old overweight (OO) males. 
 Gene YL OL OO 
Fatty acid 
oxidation 
ACACB 0.79 ± 0.04 0.83 ± 0.24 1.38 ± 0.12
*†
 
CPT1B 1.01 ± 0.25 3.38 ± 1.38 1.76 ± 0.44 
CPT2 0.83 ± 0.07 0.90 ± 0.18 1.02 ± 0.17 
HADHB 0.70 ± 0.07 1.33 ± 0.22
+
 0.83 ± 0.14
†
 
ACADM 0.57 ± 0.08 0.73 ± 0.04 0.63 ± 0.08 
ACAT1 0.55 ± 0.09 0.74 ± 0.10 0.66 ± 0.09 
IMCL turnover SPTLC1 0.81 ± 0.09 1.19 ± 0.21 1.29 ± 0.12
*
 
DGKD 1.05 ± 0.11 1.15 ± 0.24 1.59 ± 0.13
*
 
DGAT1 0.87 ± 0.06 1.00 ± 0.13 1.12 ± 0.08 
PLIN2 1.15 ± 0.10 1.98 ± 0.30
+
 1.24 ± 0.16
†
 
PLIN5 0.93 ± 0.22 1.24 ± 0.26 1.24 ± 0.28 
PNPLA2 0.74 ± 0.07 0.63 ± 0.16 0.62 ± 0.08 
All values (n=7) are means ± standard error of the mean (SEM) and expressed as relative 
mRNA abundance compared to a YL comparator. *P<0.05, OO different to corresponding 
YL value.
 †
P<0.05, OO different to corresponding OL value. 
+
P<0.05, OL different to 
corresponding YL value. 
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FIGURE LEGENDS 
 
Figure 1. Insulin sensitivity index (A), skeletal muscle 2-deoxyglucose-6-phosphate 
accumulation (B), plasma 2-deoxyglucose concentration (C), and whole-body energy 
expenditure (D) during a 3 h  hyperinsulinaemic (60mU m
-2 
min
-1
) euglycaemic clamp in 
young lean (YL, white squares), old lean (OL, black circles), and old overweight (OO, white 
circles) males. Values represent mean ± SEM (n=7). *P<0.05, ** P<0.01, OO different to 
corresponding YL value. 
†
P<0.05, 
††
P<0.01, OO different to corresponding OL value. 
^
P<0.05, 
^^
P<0.01, different to corresponding baseline value. 
 
Figure 2. Fasting skeletal muscle diacylglycerol (A) and ceramide content  (B) in young lean 
(white bars), old lean (black bars), and old overweight (hatched bars) males. Values represent 
mean ± SEM (n=7). *P<0.05, old overweight different to corresponding young lean value. 
†
P<0.05, old overweight different to corresponding old lean value. 
 
Figure 3.  Whole-body energy expenditure (A), plasma FFA rate of disappearance (Rd; B), 
percentage of plasma FFA Rd oxidised (C), and plasma noradrenaline concentration (D) 
during 1 h of cycling exercise at 50% VO2max in young lean (YL, white squares), old lean 
(OL, black circles), and old overweight (OO, white circles) males. The contribution of IMCL 
to whole-body energy expenditure in 3A assumes non-plasma FFA oxidation is 
predominantly IMCL. Values represent mean ± SEM (n=7). *P<0.05, ** P<0.01, OO 
different to corresponding YL value. 
+
P<0.05, 
++
P<0.01, OL different to corresponding YL 
value. 
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Figure 4.  Percentage area of subsarcolemmal (SSL) region covered by lipid droplets (LD; 
A), average SSL LD size (B), percentage area of intermyofibrillar (IMF) region covered by 
LD (C), and average IMF LD size (D) from electron micrographs of skeletal muscle samples 
taken before (pre exercise) and after (post exercise) 1 h of cycling exercise at 50% VO2max 
in young lean (white bars), old lean (black bars), and old overweight (hatched bars) males. 
Values represent mean ± SEM (n=7). *P<0.05, ** P<0.01, old overweight different to 
corresponding young lean value. 
†
P<0.05, 
††
P<0.01, old overweight different to corresponding 
old lean value. 
^
P<0.05, different to corresponding pre exercise value. 
 
Figure 5.  Skeletal muscle glycogen (A), phosphocreatine (B), lactate (C), and acetylcarnitine 
(D) content before (pre exercise) and after (post exercise) 1 h of cycling exercise at 50% 
VO2max in young lean (white bars), old lean (black bars), and old overweight (hatched bars) 
males. Values represent mean ± SEM (n=7). *P<0.05, old overweight different to 
corresponding young lean value. 
†
P<0.05, old overweight different to corresponding old lean 
value. 
^
P<0.05, 
^^^
P<0.001, different to corresponding pre exercise value. 
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